CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the pricing of a public offering of 2,400,000 shares of common stock at a public offering price of $50.00 per share, before underwriting discounts. In addition, Acceleron has granted the underwriters a 30-day option to purchase up to an additional 360,000 shares of common stock at the public offering price, less underwriting discounts. The offering is expected to close on or about January 28, 2014, subject to satisfaction of customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
